Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02787304 · ClinicalTrials.gov registry record · Phase 2
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Mirum Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
NCT02787304 is a Phase 2 study that was terminated before completion, run by Mirum Pharmaceuticals. The registered enrollment target is 197 participants.
The verdict
NCT02787304, a Phase 2 study, was terminated before completion, sponsored by Mirum Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the investigational treatment volixibat (SHP626) is safe, tolerable and effective in adults with nonalcoholic steatohepatitis (NASH).
Interventions
- DRUG Placebo
- DRUG SHP626
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2016-10-24 |
| Est. Completion | 2018-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02787304
The ClinicalTrials.gov registry entry for NCT02787304 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mirum Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02787304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02787304 about?
NCT02787304 is a clinical study titled "Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)". The purpose of this study is to determine if the investigational treatment volixibat (SHP626) is safe, tolerable and effective in adults with nonalcoholic steatohepatitis (NASH).
What is the current status of trial NCT02787304?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2016-10-24. Estimated completion is 2018-07-27.
What interventions are being tested in trial NCT02787304?
The interventions under investigation include: Placebo (DRUG), SHP626 (DRUG).
Who is sponsoring clinical trial NCT02787304?
This trial is sponsored by Mirum Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.